Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of "Moderate Buy" by Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $8.50.

A number of brokerages have commented on ANRO. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Alto Neuroscience in a research note on Monday. Wedbush reissued a "neutral" rating and issued a $4.00 price objective on shares of Alto Neuroscience in a research note on Thursday, May 15th.

Alto Neuroscience Trading Up 6.4%

NYSE ANRO traded up $0.23 during trading hours on Monday, hitting $3.82. 7,969 shares of the company's stock were exchanged, compared to its average volume of 259,303. The stock has a 50-day simple moving average of $2.77 and a 200 day simple moving average of $2.72. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $15.04. The firm has a market cap of $103.43 million, a price-to-earnings ratio of -1.60 and a beta of 1.84. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). On average, equities analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after acquiring an additional 3,139 shares during the period. Deutsche Bank AG grew its stake in Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after acquiring an additional 3,629 shares during the period. Jane Street Group LLC grew its stake in Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after acquiring an additional 7,783 shares during the period. AlphaCore Capital LLC grew its stake in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock valued at $44,000 after acquiring an additional 10,000 shares during the period. Finally, Barclays PLC boosted its position in shares of Alto Neuroscience by 34.5% during the fourth quarter. Barclays PLC now owns 39,807 shares of the company's stock valued at $168,000 after buying an additional 10,208 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.